Clinical Trial Update: SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial compares SHR-A1811 with Pyrotinib plus Capecitabine in trastuzumab-resistant HER2-positive advanced breast cancer; the study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib/Capecitabine
• SHR-A1811

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING